Trial Profile
Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GSK Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Jun 2023
Price :
$35
*
At a glance
- Drugs GSK 137173A (Primary)
- Indications Herpes zoster
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 07 Oct 2018 Results presented at the IDWeek 2018
- 19 Sep 2018 Status changed from active, no longer recruiting to completed.
- 31 Mar 2017 Status changed from recruiting to active, no longer recruiting.